Two groups are fighting for an edge in one of the most lucrative drug classes in the pharmaceutical industry’s history.

Leif Stromnes returns to B&T with this read that will have you questioning everything you held certain. Well, almost ...

Two years later, those treatments have thrust Metsera to the centre of a fierce takeover battle, with Ozempic maker Novo Nordisk and Pfizer willing to pay up to $10bn for the company. Both once again ...

Review the Millerton Retail case study hosted at https://example.com/doc/2bTzQx and answer the prompt provided in the linked document. Keep the exam tab open and view the case details in a separate ...